Rikiya Nakamura

6PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 16, 2026
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.

|Mar 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando

|May 20, 2024
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).

Toshimi Takano, Norikazu Masuda, Mitsuya Ito

|Apr 18, 2024
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.

Masaya Hattori, Victoria Serelli-Lee, Yoichi Naito

|Mar 08, 2021
Clinical impact of the biology of synchronous axillary lymph node metastases in primary breast cancer on preoperative treatment strategy.

Rikiya Nakamura, Shouko Hayama, Itaru Sonoda

|Jul 24, 2017
Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.

Rikiya Nakamura, Naohito Yamamoto, Toshiko Miyaki

Pageof 1

Frequent Collaborators

3 joint publications

Norikazu Masuda

3 joint publications

Hiroko Bando

2 joint publications

Hiroyuki Yasojima

2 joint publications

Shigenori E Nagai